Cellectar Biosciences, Inc. (CLRB) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-14

Key Insights

Cellectar reported Q1 2026 financial results on May 14, 2026, indicating the company is actively monitoring and communicating quarterly performance to investors.
The filing is a standard quarterly earnings announcement (8-K Item 2.02) with no indication of material events, acquisitions, leadership changes, or other significant corporate developments beyond routine financial reporting.
Company remains listed on Nasdaq Capital Market under ticker CLRB with headquarters in Florham Park, NJ, suggesting stable operational status with active SEC compliance.
The lack of any Material Agreements (Item 1.01), Financial Statements (Item 5.02 leadership changes), or Bankruptcy disclosures indicates no major corporate disruptions or strategic pivots during the quarter.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-08

Cellectar raised capital through a registered direct offering of 1.6M shares plus a concurrent private placement totaling 2.1M shares and warrant packages, indicating the company needed to strengthen its balance sheet for clinical development.
The offering includes milestone-based warrants tied to key clinical and regulatory events (pivotal trial initiation, NDA acceptance, and NDA approval) for iopofosine I-131, aligning investor returns with the company's clinical pipeline progress.
Management team participation in the private placement at $2.88 per share demonstrates insider confidence, though this represents potential dilution for existing shareholders with approximately 3.7M additional shares entering the market.
The company has 60 days from May 4, 2026 to register the resale of unregistered shares, creating a near-term overhang risk and potential selling pressure once registration becomes effective.

Filed: 2026-03-04

Cellectar Biosciences reported its full-year 2025 financial results, providing an update on the company's corporate developments.
The company did not provide any new information on the progress of its clinical pipeline or provide financial guidance for the upcoming year.
Without any major news or updates, this 8-K filing appears to be a routine disclosure of the company's annual financial performance.

Other reports for Cellectar Biosciences, Inc.

Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.